Review: Antiplatelet drugs: what comes next?

dc.contributor.authorKei, A. A.en
dc.contributor.authorFlorentin, M.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorLiberopoulos, E. N.en
dc.date.accessioned2015-11-24T18:53:31Z
dc.date.available2015-11-24T18:53:31Z
dc.identifier.issn1938-2723-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18574
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectDrug Hypersensitivity/etiologyen
dc.subjectHumansen
dc.subjectPlatelet Aggregation Inhibitors/*adverse effects/*classification/*therapeutic useen
dc.subjectThrombosis/drug therapy/mortalityen
dc.titleReview: Antiplatelet drugs: what comes next?en
heal.abstractAntiplatelet drugs are important components in the management of atherothrombotic vascular disease. However, several limitations restrict the safety and efficacy of current antiplatelet therapy in clinical practice. Interpatient variability and resistance to aspirin and/or clopidogrel has spurred efforts for the development of novel agents. Indeed, several antiplatelet drugs are at various stages of evaluation; those at advanced stage of development are the focus of this review.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1177/1076029610385222-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21078606-
heal.identifier.secondaryhttp://cat.sagepub.com/content/17/1/9.full.pdf-
heal.journalNameClin Appl Thromb Hemosten
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2011-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: